Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of anti-CD7 CAR T cells in pediatric and young adult patients with relapsed/refractory CD7-positive T-cell acute lymphoblastic leukemia/lymphoma
2023-508355-39-00Phase 2Authorised
- Sponsor
- Ospedale Pediatrico Bambino Gesù
- Start
- Apr 2024
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of CD7-CART01 in t-cell acute lymphoblastic leukemia (T-ALL) and lymphoblastic lymphoma (LL) (2 arms), sponsored by Ospedale Pediatrico Bambino Gesù. Primary endpoints: Safety and dose-limiting toxicity and Day 28 MRD-negative remission rate. Planned start Apr 2024; status: authorised.
02
Drugs
CD7-CART01
03
Conditions
t-cell acute lymphoblastic leukemia (T-ALL)lymphoblastic lymphoma (LL)
Beyond the preview
Go deeper on 2023-508355-39-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508355-39-00.